• Ability to understand and the willingness to sign a written informed consent document.

• Age ≥ 18 years and ≤ 80 years.

• Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

• Histologically or cytologically confirmed advanced pancreas adenocarcinoma.

• Tumor progression after at least one line of chemotherapy.

• Genetic or molecular test confirmed the presence of homologous recombination deficiency.

• Presence of at least of one measurable lesion in agreement to RECIST criteria.

• The expected survival ≥ 3 months.

• Adequate organ performance based on laboratory blood tests.

• Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation.